Your Money or Your Life: Patient on $50,000-a-Week Cancer Drug Fears Leaving Behind Huge Medical Debt
When Medicare stops paying for a pricey drug that prolongs life, an Ohio man considers giving up treatment to spare his family enormous debt.
The independent source for health policy research, polling, and news.
81 - 100 of 230 Results
When Medicare stops paying for a pricey drug that prolongs life, an Ohio man considers giving up treatment to spare his family enormous debt.
The proportion of Californians dying at home, rather than in a hospital or nursing home, accelerated during the pandemic, a trend that has outlasted the rigid lockdowns linked to the initial shift.
When Penelope Wingard's cancer went into remission, she lost her Medicaid coverage in North Carolina. Without insurance, the debts piled up for her follow-up care. She doesn't think she'll ever get ahead of it.
Monica Reed was the first in her family to own a home and has lived "a frugal kind of life." Cancer treatment left her with almost $10,000 in debt, pushing her to the edge financially.
Improving lung cancer outcomes in Black communities will take more than lowering the screening age, experts say. Disparities are present in everything from the studies that inform when people should get checked to the availability of care in rural areas.
KHN gives readers a chance to comment on a recent batch of stories.
When Katie Couric announced she had breast cancer, she urged women to get a mammogram — and, if they have dense breasts, to get supplemental screening by ultrasound. But medical experts point out that ultrasound and other auxiliary screenings haven’t been proven to do more than regular mammography in reducing mortality.
Lupron, a drug patented half a century ago, treats advanced prostate cancer. It’s sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals — which may pay nearly as little for the drug — charging so much more to administer it?
Creole-speaking public health workers teach women how to test themselves for HPV, the virus that causes some cervical cancers.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Doctors are divided on whether blanket testing of breast cancer patients is warranted, since scientists and physicians are sometimes unsure about how to interpret the results.
As abortion restrictions take effect across the South in the wake of the Supreme Court’s decision to overturn Roe v. Wade, cancer doctors are trying to decipher the laws. They’re grappling with how to discuss options with pregnant patients, who may be forced to choose whether to proceed or forgo lifesaving cancer treatments that can prove toxic for the fetus.
A federal judge in Texas issued a decision this week that affects the Affordable Care Act. It says one way that preventive services are selected for no-cost coverage is unconstitutional.
Chimeric antigen receptor T-cell therapy has eliminated tumors in some late-stage cancer patients, but the cost and complexity of care mean rural Americans have trouble accessing the treatment.
An online calculator told a young woman that a procedure to rule out cancer would cost an uninsured person about $1,400. Instead, the hospital initially charged almost $18,000 and, with her high-deductible health insurance, she owed more than $5,000.
Inflation hasn’t hit Americans like this in decades. And families living with chronic diseases have little choice but to pay more for the medicine, supplies, and food they need to stay healthy.
Le Roy and Rosie Torres founded the Burn Pits 360 group that advocated for years for Congress to help veterans suffering from injuries caused by the massive disposal sites on overseas bases. Le Roy came home from Iraq suffering from breathing problems.
Private equity firms are seeing opportunities for profit in hospice care, once the domain of nonprofit organizations. The investment companies are transforming the industry — and might be jeopardizing patient care — in the process.
Medical breakthroughs mean cancer is less likely to kill, but survival can come at an extraordinary cost as patients drain savings, declare bankruptcy, or lose their homes, a KHN-NPR investigation finds.
© 2026 KFF